Cancer Genetics and Epigenetics 2024, Vol.12, No.5, 294-305 http://medscipublisher.com/index.php/cge 302 ovarian cancer risk, such as mutations in BRCA1 or BRCA2. Individuals with these hereditary mutations are at a significantly higher risk of developing ovarian cancer, and early detection allows for more proactive interventions. By combining gene editing with liquid biopsy technologies, which can detect circulating tumor DNA or other cancer markers, researchers aim to identify the presence of cancer at its earliest stages. In addition to detection, gene editing may also be applied to prevent cancer in individuals with high genetic risk. For example, correcting BRCA1 or BRCA2 mutations using CRISPR in at-risk individuals could prevent the onset of cancer altogether (Dunbar et al., 2018). While still in the experimental stage, these applications represent a promising future direction for gene editing in cancer prevention. Ethical concerns and technical challenges, such as off-target effects and the delivery of gene editing tools, must be addressed before these strategies can be widely implemented. However, as gene editing technologies advance, they hold significant potential to transform the early detection and prevention landscape of ovarian cancer. 6.4 Potential of epigenetic editing in cancer treatment Epigenetic modifications, such as DNA methylation and histone modifications, play a significant role in the progression of ovarian cancer. Unlike genetic mutations, epigenetic changes do not alter the DNA sequence but rather regulate gene expression, often leading to the silencing of tumor suppressor genes or the activation of oncogenes. Epigenetic editing offers a precise way to reverse these changes. Tools like CRISPR-dCas9 can be used to target specific epigenetic modifications, reactivating silenced tumor suppressor genes or suppressing overactive oncogenes without altering the DNA sequence itself. For example, epigenetic editing could be used to demethylate the BRCA1 promoter, restoring its expression and improving the cell's ability to repair DNA damage (Xie et al., 2021). Furthermore, combining epigenetic editing with traditional treatments, such as chemotherapy, could help overcome drug resistance by restoring the sensitivity of cancer cells to these therapies. The future of epigenetic editing holds great promise in ovarian cancer treatment, as it offers an additional layer of precision by targeting not only genetic mutations but also the epigenetic changes that contribute to cancer progression and resistance. As research in this area continues, epigenetic editing could become a critical component of personalized cancer therapies, providing a more comprehensive approach to overcoming the complexities of ovarian cancer. 7 Concluding Remarks Gene editing technologies, particularly CRISPR-Cas9, have transformed the landscape of ovarian cancer research and hold immense promise for the future of cancer therapy. The integration of gene editing with precision medicine, immunotherapy, and early detection offers new avenues for more effective treatments. However, challenges such as delivery, ethical concerns, and tumor heterogeneity must be addressed to unlock the full potential of gene editing in clinical applications. Gene editing technologies have significantly advanced the understanding and treatment of ovarian cancer, particularly in targeting key genetic mutations such as BRCA1, BRCA2, TP53, and KRAS. CRISPR-Cas9 and other gene editing tools have been successfully applied in preclinical models to investigate these mutations, correct genetic defects, and improve the effectiveness of cancer therapies, including chemotherapy, PARP inhibitors, and immunotherapies. Additionally, epigenetic editing has emerged as a promising strategy to reverse the aberrant gene silencing or activation associated with cancer progression. However, despite these advances, major challenges remain, such as achieving high precision in gene editing, delivering these technologies effectively to tumors, and addressing the issue of tumor heterogeneity, which can lead to resistance and relapse. Nonetheless, the progress made over the last decade underscores the transformative potential of gene editing in ovarian cancer research. Looking ahead, gene editing has the potential to revolutionize ovarian cancer treatment by enabling more personalized and targeted approaches. In the future, gene editing technologies could be integrated with existing treatments to enhance their efficacy and overcome drug resistance. For instance, combining gene editing with
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==